Failure to detect the 22q11.2 duplication syndrome rearrangement among patients with schizophrenia.

Behav Brain Funct

Genes and Disease Program, Barcelona Genotyping Node, CeGen-CRG, CIBER en Epidemiología y Salud Pública (CIBERESP), Center for Genomic Regulation (CRG-UPF), Barcelona, Catalonia, Spain.

Published: February 2008

Chromosome aberrations have long been studied in an effort to identify susceptibility genes for schizophrenia. Chromosome 22q11.2 microdeletion is associated with DiGeorge and Velocardiofacial syndromes (DG/VCF) and provides the most convincing evidence of an association between molecular cytogenetic abnormality and schizophrenia. In addition, this region is one of the best replicated linkage findings for schizophrenia. Recently, the reciprocal microduplication on 22q11.2 has been reported as a new syndrome. Preliminary data indicates that individuals with these duplications also suffer from neuropsychiatric disorders. In this study we have investigated the appropriateness of testing schizophrenia patients for the 22q11.2 microduplication. We used multiplex ligation-dependent probe amplification (MLPA) to measure copy number changes on the 22q11.2 region in a sample of 190 patients with schizophrenia. Our results corroborate the prevalence of the 22q11.2 microdeletion in patients with schizophrenia and clinical features of DG/VCFS and do not suggest an association between 22q11.2 microduplication and schizophrenia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2278148PMC
http://dx.doi.org/10.1186/1744-9081-4-10DOI Listing

Publication Analysis

Top Keywords

patients schizophrenia
12
schizophrenia
8
schizophrenia chromosome
8
22q112 microdeletion
8
22q112 microduplication
8
22q112
7
failure detect
4
detect 22q112
4
22q112 duplication
4
duplication syndrome
4

Similar Publications

Background: Glial cell line-derived neurotrophic factor (GDNF) has emerged as a potential biomarker for schizophrenia (SCZ). However, GDNF levels remain unclear in affected individuals compared to healthy controls. Therefore, we aimed to calculate a pooled estimate of GDNF levels in patients with SCZ in comparison with healthy controls.

View Article and Find Full Text PDF

Distribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.

Psychiatry Res

January 2025

South Carolina Department of Mental Health, 220 Executive Dr, Greer, SC 29651, United States; Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 15 Medical Park, Suite 301, Columbia, SC 29203, United States.

Although long-acting injectable antipsychotics (LAIs) are an important pharmaceutical option in the management of schizophrenia and related disorders, little is known about patient characteristics related to LAI use in real-world outpatient settings. We analyzed electronic medical records from 41,401 patients who received psychiatric services from one of 16 regional mental health centers operated by the South Carolina Department of Mental Health in 2022. We compared the use of first- and second-generation LAIs and oral antipsychotics by sociodemographic (age, gender, race/ethnicity, zip code, payment source) and clinical characteristics (psychiatric diagnoses, service use).

View Article and Find Full Text PDF

Delusional misidentification syndromes (DMS) are rare neuropsychiatric syndromes. Most of the available data on DMS is from the developed countries. The present retrospective analysis was conducted on patients utilizing the psychiatry services in a North Indian tertiary care hospital.

View Article and Find Full Text PDF

Rising studies have consistently reported gut bacteriome alterations in schizophrenia (SCZ). However, little is known about the role of the gut virome on shaping the gut bacteriome in SCZ. Here in, we sequenced the fecal virome, bacteriome, and host peripheral metabolome in 49 SCZ patients and 49 health controls (HCs).

View Article and Find Full Text PDF

Introduction: While antipsychotics are key requirement in acute and long-term management of schizophrenia, medication adherence remains a major unmet need in its care. This paper assessed the prevalence of oral antipsychotic non-adherence among outpatients with schizophrenia and its associated clinico-demographic factors.

Method: Three hundred and ten adult outpatients (18-64 years of age) were cross-sectionally interviewed after being diagnosed of schizophrenia using ICD-10 criteria, and the diagnosis confirmed with the Mini International Neuropsychiatric Interview (MINI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!